BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yokoda R, Nagalo BM, Vernon B, Oklu R, Albadawi H, DeLeon TT, Zhou Y, Egan JB, Duda DG, Borad MJ. Oncolytic virus delivery: from nano-pharmacodynamics to enhanced oncolytic effect. Oncolytic Virother 2017;6:39-49. [PMID: 29184854 DOI: 10.2147/OV.S145262] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Nagalo BM. Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We? Front Immunol 2022;13:898631. [DOI: 10.3389/fimmu.2022.898631] [Reference Citation Analysis]
2 Volovat S, Ursulescu CL, Moisii LG, Volovat C, Boboc D, Scripcariu D, Amurariti F, Stefanescu C, Stolniceanu CR, Agop M, Lungulescu C, Volovat CC. The Landscape of Nanovectors for Modulation in Cancer Immunotherapy. Pharmaceutics 2022;14:397. [DOI: 10.3390/pharmaceutics14020397] [Reference Citation Analysis]
3 Horowitz NB, Mohammad I, Moreno-Nieves UY, Koliesnik I, Tran Q, Sunwoo JB. Humanized Mouse Models for the Advancement of Innate Lymphoid Cell-Based Cancer Immunotherapies. Front Immunol 2021;12:648580. [PMID: 33968039 DOI: 10.3389/fimmu.2021.648580] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
4 Briolay T, Petithomme T, Fouet M, Nguyen-Pham N, Blanquart C, Boisgerault N. Delivery of cancer therapies by synthetic and bio-inspired nanovectors. Mol Cancer 2021;20:55. [PMID: 33761944 DOI: 10.1186/s12943-021-01346-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
5 Jin KT, Du WL, Liu YY, Lan HR, Si JX, Mou XZ. Oncolytic Virotherapy in Solid Tumors: The Challenges and Achievements. Cancers (Basel) 2021;13:588. [PMID: 33546172 DOI: 10.3390/cancers13040588] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
6 Macedo N, Miller DM, Haq R, Kaufman HL. Clinical landscape of oncolytic virus research in 2020. J Immunother Cancer 2020;8:e001486. [PMID: 33046622 DOI: 10.1136/jitc-2020-001486] [Cited by in Crossref: 27] [Cited by in F6Publishing: 65] [Article Influence: 13.5] [Reference Citation Analysis]
7 Cook M, Chauhan A. Clinical Application of Oncolytic Viruses: A Systematic Review. Int J Mol Sci 2020;21:E7505. [PMID: 33053757 DOI: 10.3390/ijms21207505] [Cited by in Crossref: 7] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
8 Lim J, Cho E, Lee K, Choi Y, Seo Y, Jeon H, Choi J. Current Immunotherapy Approaches for Malignant Melanoma. BioChip J 2019;13:105-14. [DOI: 10.1007/s13206-019-3108-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
9 Yokoda R, Nagalo BM, Arora M, Egan JB, Bogenberger JM, DeLeon TT, Zhou Y, Ahn DH, Borad MJ. Oncolytic virotherapy in upper gastrointestinal tract cancers. Oncolytic Virother. 2017;7:13-24. [PMID: 29616200 DOI: 10.2147/ov.s161397] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
10 Yokoda RT, Nagalo BM, Borad MJ. Oncolytic Adenoviruses in Gastrointestinal Cancers. Biomedicines. 2018;6. [PMID: 29534501 DOI: 10.3390/biomedicines6010033] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]